PiSCATIN study reaches full recruitment milestone
PiSCATIN study reaches full recruitment milestone
Professor Annika Bergquist
The PiSCATIN clinical trial, which is evaluating the use of simvastatin in patients with primary sclerosing cholangitis (PSC), has successfully reached its recruitment target. A total of 570 participants have been enrolled in the study, and recruitment officially closed on 15 April 2025.
What is the current status of the study?
The study is now in the treatment and monitoring phase. A new batch of study medication has been received, ensuring that all participants can continue their treatment according to the protocol. The study team is also conducting ongoing quality control of data from the first 25 participants who have already completed the study.
When will the results be available?
While the study is progressing well, clinical trials require significant time to ensure findings are robust and accurate. The timeline for the interim analysis has been updated and is currently scheduled for March 2027. This analysis will provide vital insights into the progress and safety of the treatment.
Why is this research important?
PSC is a rare, immune-mediated liver disease that currently has no proven medical treatment to stop or slow its progression. By investing in trials like PiSCATIN, PSC Support aims to unlock the understanding of disease processes and establish evidence-based treatments that can improve health outcomes for the PSC community.
Turning Ambition into Action in 2026:
Our Fortnight in Focus
At PSC Support, we want a world without PSC. We work tirelessly behind the scenes to drive research and improve lives. Here is a snapshot of what we've been up to:
Building Partnerships: We planned our attendance at major liver and gastro events this year to ensure healthcare professionals know about PSC and the guidelines around it.
Empowering our Community: We published our monthly research roundup to keep the community informed about research progress and advocacy news.
Improving Care: We collaborated with partners to develop a standardised care pathway, aiming for consistent care for everyone with PSC.
Organisational Excellence: We discussed how to show our appreciation to our donors in a more personal way.
Organisational Excellence: We provided research impact data to the Association of Medical Research Charities to maintain our high standards of transparency in research.
Organisational Excellence: We strengthened our data management systems to better track the impact of the research projects we fund.
Organisational Excellence: We signed off our budget for 26/27 to ensure we have proper and critical oversight of our spending.
Progressing Research: We updated the Asp-PSC clinical trial sites to ensure PSC patients are up to date on where they can go to take part in the trial and we held a webinar all about it!